About 30 results found for searched term "SGLT" (0.096 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1937 | Dapagliflozin | SGLT |
| BMS-512148 | ||
| Dapagliflozin (BMS-512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). | ||
| M2667 | Empagliflozin | SGLT |
| BI 10773 | ||
| Empagliflozin (BI-10773) is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. | ||
| M4606 | Phloridzin | SGLT |
| Floridzin; NSC 2833 | ||
| Phloridzin is a non-selective SGLT inhibitor with Kis of 300 and 39 nM for hSGLT1 and hSGLT2, respectively. Phlorizin is also a Na+/K+-ATPase inhibitor. | ||
| M4607 | Phloretin | SGLT |
| NSC 407292; RJC 02792 | ||
| Phloretin (NSC 407292; RJC 02792) is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). | ||
| M5249 | Sotagliflozin | SGLT |
| LX-4211; LP-802034 | ||
| Sotagliflozin (LX-4211) is an orally active, first-in-class dual SGLT1/2 inhibitor with IC50s of 36 nM and 1.8 nM, respectively, and is used in studies related to type 1 diabetes and heart failure. | ||
| M5254 | Ipragliflozin | SGLT |
| ASP 1941 | ||
| Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. | ||
| M6200 | Ipragliflozin L-Proline | SGLT |
| Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion by inhibiting renal glucose reabsorption and thereby causes a subsequent antihyper-glycemic effect. | ||
| M6272 | Ertugliflozin | SGLT |
| MK-8835, PF-04971729 | ||
| Ertugliflozin (MK-8835, PF-04971729) is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2). | ||
| M8010 | Phloridzin dihydrate | Others |
| Competitive inhibitor of SGLT1 and SGLT2. | ||
| M8956 | Canagliflozin hemihydrate | SGLT |
| JNJ-28431754; TA 7284 | ||
| Canagliflozin hemihydrate (JNJ-28431754; TA 7284) is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM. | ||
| M9738 | LX2761 | SGLT |
| LX2761 is a locally acting SGLT1 and SGLT2 inhibitor in vitro with IC50 values of 2.2 nM and 2.7 nM for hSGLT1 and hSGLT2, respectively. | ||
| M10441 | Tofogliflozin (hydrate) | SGLT |
| CSG-452 hydrate | ||
| Tofogliflozin (CSG-452) hydrate is a potent and highly specific sodium-glucose co-transporter 2(SGLT2) inhibitor with IC50 value of 2.9 nM. | ||
| M11497 | Trilobatin | HIV Protease |
| P-Phlorizin | ||
| Trilobatin (P-phlorizin) is a natural flavonoid lipid molecule that is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope and has antioxidant and anti-inflammatory effects. Trilobatin is also an SGLT1/2 inhibitor that selectively induces human hepatoblastoma cell proliferation. | ||
| M14269 | Ertugliflozin L-pyroglutamic acid | SGLT |
| PF-04971729 L-pyroglutamic acid | ||
| Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. | ||
| M20730 | KGA-2727 | SGLT |
| KGA-2727 is a potent, selective, high-affinity inhibitor of sodium glucose cotransporter 1 (SGLT1) with Ki of 97.4 nM and 43.5 nM for human SGLT1 and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 exhibits antidiabetic efficacy in rodent models. | ||
| M20844 | Bexagliflozin (EGT1442) | SGLT |
| EGT-0001442, THR-1442 | ||
| Bexagliflozin (EGT1442, EGT-0001442, THR-1442) is a potent and selective SGLT2 inhibitor with an IC50 of 2 nM. | ||
| M20997 | Remogliflozin etabonate (GSK189075) | SGLT |
| Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity inhibitor of sodium glucose cotransporter (SGLT2) with Ki of 1950 nM, 2140 nM, 43100 nM, 8570 nM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models. | ||
| M21066 | GCC5694A | Others |
| GCC5694A is an oral SGLT2 inhibitor. SGLT2 inhibitors help people with diabetes control their blood sugar by preventing glucose reabsorption in the kidneys. | ||
| M21456 | Enavogliflozin | SGLT |
| DWP-16001 | ||
| Enavogliflozin (DPW-16001), an antidiabetic compound, is a first class selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor with oral activity. | ||
| M27633 | Kushenol K | Cytochrome P450 (e.g. CYP17) |
| K | ||
| Kushenol K, a flavonoid antioxidant isolated from the roots of Sophora flavescens. Kushenol K is a cytochrome P-450 3A4 (CYP3A4) inhibitor with a Ki value of 1.35 μM. Kushenol K shows weak antiviral activity against HSV-2 (EC50 of 147 μM). Kushenol K also inhibits the activity of SGLT1 and SGLT2. | ||
| M27858 | Luseogliflozin hydrate | SGLT |
| TS 071 hydrate | ||
| Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM). | ||
| M28119 | Licogliflozin | SGLT |
| LIK066 | ||
| Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor. | ||
| M29219 | T-1095 | SGLT |
| T-1095 is a selective and orally active Na+-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research. | ||
| M29920 | Remogliflozin | SGLT |
| Remogliflozin A | ||
| Remogliflozin is a potent and selective inhibitor of SGLT2 (sodium-glucose cotransporter 2) with Kis of 12.4 and 26 nM for human and rat SGLT2, respectively. | ||
| M30056 | Sergliflozin etabonate | SGLT |
| GW-869682X | ||
| Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes. | ||
| M30450 | Mizagliflozin | SGLT |
| DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base | ||
| Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation. | ||
| M30847 | Tofogliflozin | SGLT |
| CSG452 | ||
| Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2. | ||
| M31403 | JP-2266 | SGLT |
| JP-2266 is a dual SGLT1/2 inhibitor that can be used in studies related to diabetes. | ||
| M31404 | JTT-662 | SGLT |
| JTT-662 is an SGLT1 inhibitor that can be used in studies related to type 2 diabetes. | ||
| M31405 | Tianagliflozin | SGLT |
| Tianagliflozin is an SGLT2 inhibitor that may be used in studies related to type 2 diabetes. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
